Avalo Therapeutics

Recent news

• Piper Sandler Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $60
  Market Newswire · 2026/10/1
• Rating change
  Wolfe Research Initiates Avalo Therapeutics(AVTX.US) With Buy Rating, Announces Target Price $48
  Market Newswire · 2026/4/9
• Rating change
  BTIG Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Raises Target Price to $58
  Market Newswire · 2026/5/6
• Leerink Partners Initiates Avalo Therapeutics(AVTX.US) With Buy Rating, Announces Target Price $38
  Market Newswire · 2026/7/6
• Rating change
  Piper Sandler Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Raises Target Price to $60
  Market Newswire · 2026/5/11
• Rating change
  Citizens JMP Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Raises Target Price to $62
  Market Newswire · 2026/5/6
• Rating change
  Stifel Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $36
  Market Newswire · 2026/5/7
• Rating change
  H.C. Wainwright Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Raises Target Price to $40
  Market Newswire · 2026/3/25
• Rating change
  Piper Sandler Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $48
  Market Newswire · 2026/3/30
• Rating change
  A Quick Look at Today's Ratings for Avalo Therapeutics(AVTX.US), With a Forecast Between $34 to $58
  Market Newswire · 2026/5/14
• Guggenheim Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Cuts Target Price to $48
  Market Newswire · 2026/8/7
• Rating change
  Citizens JMP Initiates Avalo Therapeutics(AVTX.US) With Buy Rating, Announces Target Price $52
  Market Newswire · 2026/4/6
• Rating change
  TD Cowen Maintains Avalo Therapeutics(AVTX.US) With Buy Rating
  Market Newswire · 2026/6/11
• A Quick Look at Today's Ratings for Avalo Therapeutics(AVTX.US), With a Forecast Between $30 to $58
  Market Newswire · 2026/8/7
• Company notice
  Avalo Therapeutics: Avalo Therapeutics, Inc. - Reverse Split Option Symbol: AVTX New Symbol: AVTX1
  OCC · 2022/7/7
• BofA Securities Initiates Avalo Therapeutics(AVTX.US) With Buy Rating, Announces Target Price $35
  Market Newswire · 2026/6/12
• Rating change
  A Quick Look at Today's Ratings for Avalo Therapeutics(AVTX.US), With a Forecast Between $34 to $55
  Market Newswire · 2026/5/15
• Rating change
  Guggenheim Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $50
  Market Newswire · 2026/5/7
• Rating change
  Wedbush Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $29
  Market Newswire · 2026/4/16
• Rating change
  BTIG Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Maintains Target Price $58
  Market Newswire · 2026/5/6

Headlines are aggregated automatically and are not independently verified or edited by our team.